• E-mail :[email]
  • Phone : +33140011332
  • Location : Paris, France
Last update 2011-03-27 17:29:59.864

Jacqueline Capeau MD, PhD

Course and current status

CAPEAU  Jacqueline

Professor of University in Cell Biology-Hospital Practitioner in Biochemistry (PU-PH CE)


- Medical studies, MD degree (Saint Antoine Medical School, Paris VI University, 1975) 

- PhD in Biochemistry (Paris VI University), A level (1978)

- Thesis (over the PhD)  (Paris VI University), A level (1983)

Teaching responsibilities

- Professor in biochemistry and cell biology for medical students, Faculty of Medicine Pierre and Marie Curie,

Hospital responsibilities

-  Head of the Department of Biochemistry and Hormonology of the Tenon Hospital (1999 ð)

Research responsibilities

-  Director of the Unit INSERM U. 181 then 402 (1990-2005)

-  Head of the coordinated action 22 "Lipodystrophies and Metabolic Alterations" ANRS, French National Agency against AIDS and Viral Hepatitis

-  Head of new coordinated group “Complications of Antiretroviral Treatment and Aging”, ANRS, French National Agency against AIDS and Viral Hepatitis

-  Director of the Research Center Saint-Antoine UMRS938 (2008ð)


- Knight of the Academic Palms

- Knight of the National Order of the Merit

- Knight of  “Ordre National de la Légion d’Honneur”


- Regular reviews for journals: NEJM, Lancet, PNAS, FASEB J, AIDS, Antiviral Therapy, Journal of Clinical Endocrinology and Metabolism, Brain, JAIDS, Diabetes, Diabetologia…(about 30 accepted per year)

- Member of the Editorial Board of Journal of Clinical Endocrinology and Metabolism, Endocrine Society, USA (2007ð2010)

- Member of the Editorial Board of Antiviral Therapy, UK (2011ð2013)

- Expert for Efficacy and Mechanism Evaluation Programme, EME, UK

- Expert for the French Ministery of National Education MENESR,

- Regular expert for VLM (French CF association), ANR, ANRS, INSERM, AERES

- Regular expert for PhD and HDR

Invited Conférences in international meetings

- Some plenary conferences in international meetings since 2002

- 10th Conference on retroviruses and opportunistic infections (CROI), Boston, February 2003

- 2nd International AIDS Society Conference, Paris, July 2003

- European AIDS Clinical Society Conference, Warsaw, October 2003

- Novartis foundation symposia on nuclear organization in development and disease, London, January 2004

-13th International Symposium on HIV and emerging infectious diseases Toulon, June 2004

-12th International Congress of Endocrinology Lisbonne, September 2004

- Triglycerides and HDL Role in Cardiovascular Disease and Metabolic Syndrome, New York, July 2005

- Bioscience 2005, From Genes to Systems, Glasgow, UK, July 2005

- International Symposium on Viral Hepatitis and Liver Disease post-graduate course, Paris July 2006

- 29th meeting of the European Lipoprotein Club Tutzing, Germany September 2006

- NIH conference « Lipodystrophy and the metabolic consequences of altered fat deposition », Bethesda, Nov 2006

- ICMR Inserm workshop « Development of Biomarkers for CVD and Diabetes » New Delhi India, January 2007

- « Royal Society of Medicine, Section on Lipids in Clinical Medicine Meeting on Adipose tissue Biology and Obesity » London, May 2007

- 11th European AIDS conference, Madrid, October 2007

- « Second Workshop on Mitochondria toxicity and HIV infection » Modena, May 2008

- EMBO meeting, Eurolaminopathies, Vienna, January 2009

- Advanced seminar in developmental endocrinology, European Society for Paediatric Endocrinology: Paris, March 2009

- Touraine Foundation annual seminar « The Adipocyte » Paris, November 2009

- 17th conference on retroviruses and opportunistic infections CROI San Francisco February 2010

- 16th ISHEID Congress on HIV & Emerging Infectious Diseases Marseille March 2010

- VIH/SIDA 2010, Casablanca March 2010

- Infectious Diseases Society of Ireland (IDSI) Dublin June 2010

- British HIV Association (BHIVA) Autumn Conference London October 2010

- Joint meeting France-USA on aging, Nice October 2010

- Metabolic medicine issues in HIV infection, the Royal Society of Medicine, London, December 2010


- Member of the organizing committee of the “International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV” Paris 2003, Washington DC 2004, Dublin 2005, San Francisco 2006, Sydney 2007, London 2008, Philadelphia 2009, London 2010, Roma 2011

- Member of the Scientific committee of the “International workshop on HIV and Aging” Baltimore 2010, Baltimore 2011


231 in PubMed, H index = 42

Scientific summary

Main topics of Research

Studies on genetic and acquired diseases of adipose tissue leading to hepatic and vascular complications.

 Genetic lipodystrophies: identification of new genes and of new mutations leading to different clinical phenotypes.

 Acquired lipodystrophies secondary to antiretroviral drugs used to treat HIV infection and phenotype of premature aging: analysis of the alterations present in adipocytes and adipose tissue, fibroblasts, osteoblasts (mitochondrial dysfunction, cellular stresses, insulin resistance, inflammation, cytokine production, senescence) and the relationships between these alterations.

Reversibility of these alterations by insulin sensitizers, statins, farnesyl transferase inhibitors

 Hepatic and vascular complications: relations between adipose tissue and liver to better understand the lesions of non-alcoholic fatty liver disease and of non-alcoholic steato-hepatitis (NASH), studies on endothelial cells to understand the vascular complications in HIV-infected patients

 Clinical trials on pathophysiology and therapeutics in HIV-infected patients

Image d’exemple